Wolfgang Römer

Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Primary Chemotherapy in Breast Cancer

PURPOSE: To address the role of positron emission tomography (PET) using [18F]fluorodeoxyglucose (FDG) to monitor primary (neoadjuvant) chemotherapy in patients with locally advanced breast cancer. PATIENTS AND METHODS: Quantification of regional FDG uptake of the breast acquired after the first and second courses of chemotherapy was compared with the baseline scan in 22 patients with a total of 24 breast carcinomas. To evaluate the predictive value of PET imaging, histopathologic response after completion of chemotherapy classified as gross residual disease (GRD) or minimal residual disease (MRD) served as the gold standard. RESULTS: Significant differences in tracer uptake between nonresponding tumors (GRD) and responding lesions (MRD) were observed (P < .05) as early as after the first course of chemotherapy. Tracer uptake showed little change in tumors with GRD found later in pathologic analysis but decreased sharply to the background level in most tumors with MRD. After the first course, all responde...

Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose.

PURPOSE To evaluate the diagnostic value of position emission tomographic (PET) imaging with F-18 fluorodeoxyglucose (FDG) in differentiating between benign and malignant breast tumors. PATIENTS AND METHODS Fifty-one patients, with suspicious breast lesions newly discovered either by physical examination or by mammography, underwent PET imaging before exploratory surgery. FDG-PET images of the breast were analyzed visually and quantitatively for objective assessment of regional tracer uptake. RESULTS Primary breast cancer was identified visually with a sensitivity of 68% to 94% and a specificity of 84% to 97% depending on criteria used for image interpretation. Quantitative analysis of FDG uptake in tumors using standardized uptake values (SUV) showed a significant difference between benign (1.4 +/- 0.5) and malignant (3.3 +/- 1.8) breast tumors (P < .01). Receiver operating characteristic (ROC) curve analysis exhibited a sensitivity of 75% and a specificity of 100% at a threshold SUV value of 2.5. Sensitivity increased to 92% with a corresponding specificity of 97% when partial volume correction of FDG uptake was performed based on independent anatomic information. CONCLUSION PET imaging allowed accurate differentiation between benign and malignant breast tumors providing a high specificity. Sensitivity for detection of small breast cancer ( < 1 cm) was limited due to partial volume effects. Quantitative image analysis combined with partial volume correction may be necessary to exploit fully the diagnostic accuracy. PET imaging may be helpful as a complimentary method in a subgroup of patients with indeterminate results of conventional breast imaging.

Focal Metabolic Activation in the Predominant Left Auditory Cortex in Patients Suffering from Tinnitus: A PET Study with [18F]Deoxyglucose

Eleven patients suffering from chronic disabling tinnitus underwent an FDG-PET study (positron emission tomography with [18F]deoxyglucose). Nine tinnitus patients revealed a significantly increased metabolic activity in the left, 1 in the right primary auditory cortex (PAC, Brodmann area 41). These results were statistically significant when compared to 14 healthy control individuals without tinnitus. A negative result was obtained from a chronic tinnitus patient but who had no subjective complaints during the period of PET investigation. One patient was first investigated during a disabling tinnitus period, later during a period with tinnitus relief and again when suffering from severe tinnitus. The metabolic activity of his left PAC was in good accordance with the subjective degree of tinnitus complaints present during each PET investigation. Although for the first time these results give objective evidence of tinnitus sensation and localization, they are difficult to interpret because of the limited research data available that combine functional brain imaging and acoustic stimuli.

Positron Emission Tomography in Diagnosis and Therapy Monitoring of Patients with Lymphoma

In contrast to conventional imaging modalities, positron emission tomography using fluorodeoxyglucose detects malignant tumors by their increased glucose metabolism. In patients with Hodgkins disease or non-Hodgkins lymphoma, FDG-PET imaging has been shown to sensitively identify enhanced tracer uptake in involved lymph nodes and infiltrated tissue. This brief review will summarize the currently available information on staging of lymphoma patients in comparison with other imaging modalities. In addition, FDG PET imaging has been suggested for differentiation of viable residual or recurrent tumor and scar after tumor therapy. One of the most promising applications of PET in the future will be the metabolic evaluation of early response to tumor therapy. It is hypothesized that changes in tumor metabolism occur before significant decrease of tumor mass. Early assessment of chemotherapy might help to avoid the toxicity of an ineffective therapy. In summary, the results concerning various clinical applications of PET imaging are encouraging for further prospective trials to document the advantage of PET in diagnosis and therapy of lymphoma patients as compared to conventional strategies.

Metabolic Imaging Identifies Non-Hodgkin’s Lymphoma Infiltrating Heart

A67-year-old man was diagnosed with a lymphoblastic non-Hodgkin’s lymphoma and was found to have tumor infiltrating the right atrium, the ventricular septum, and the left ventricle. The tumor was imaged by TEE and MRT, and the diagnosis was confirmed by biopsy. After completion of six courses chemotherapy with CHOEP, no residual wall motion abnormalities or contrast changes were detectable by TEE. A follow-up MRT was not possible after pacemaker implantation became necessary because of AV conduction abnormalities. A CT scan was performed but could not be evaluated because of metal artifacts. A PET scan with FDG was performed to exclude residual tumor mass. Non-Hodgkin’s lymphomas exhibit …